miR-133a, which controls HLA-G protein stability, is decreased in ovarian, prostate, and bladder cancer, whereas miR-148/152, which also regulate HLA-G, are downregulated in hepatocellular carcinoma and gastrointestinal cancers (29). This evidence concerns the gene HLA-G and hepatocellular carcinoma.